Blow For Novartis Eye Drug Beovu As Studies Stop On Safety Worries
Intraocular Inflammation Cases Higher Than Rival
The Swiss giant Novartis has decided to halt the MERLIN, RAVEN and RAPTOR studies of Beovu "in the interests of patient safety" which will make the task of competing with the wet AMD market leader Eylea even tougher.
